// App-Quantinova.ai

BSH19‐PO‐122 : Ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: pharmacokinetics and pharmacodynamics observed in two Phase 3 randomized, multicenter studies

Researchers

Presenter

  • R. Peffault De Latour

Principal Investigators

  • L. Mitchell

  • R.A. Brodsky

  • S. Ortiz

  • A.M. Risitano

  • J.-H. Jang

  • P. Hillmen

  • A.D. Kulagin

  • R. Pradhan

  • S.T. Rottinghaus

  • R. Aguzzi

  • R.A. Wells

  • J. Szer

Medical Centers

  • Universite Paris-Diderot,

  • French Reference Center for Aplastic Anemia and PNH Hematology-Bone Marrow Transplantation, Research Institute for Microbial Diseases, Hôpital Saint-Louis AP-HP, Paris, France

  • University Hospital Monklands,North Lanarkshire,United Kingdom

  • Division of Surgical Oncology, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD

  • Alexion Pharmaceuticals, Inc., Boston, United States

  • Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy

  • Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

  • Pavlov First Saint Petersburg State Medical University, Saint‐Petersburg, Russian Federation

  • Alexion Pharmaceuticals, Inc., Boston, United States

  • Sunnybrook Health Sciences Centre, Division of Medical Oncology and Haematology, University of Toronto, Toronto, Canada

  • Clinical Haematology, Royal Melbourne Hospital, Melbourne, Australia

Locations

  • France

  • United Kingdom

  • United States

  • Italy

  • Russia

  • Canada

  • Australia

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Paroxysmal nocturnal hemoglobinuria

Biomarkers

  • Lactate dehydrogenase

Drug/Treatment

  • Eculizumab

  • ALXN-1210

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Pharmacodynamics

  • Non Inferiority

  • Multicenteric

  • Dose Escalation

Phase

  • III

Study Id's

  • NCT02946463

  • NCT030560040

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved